Printer Friendly

BIOCHEM PHARMA: INTERIM DATA FROM PHASE I/II 3TC TRIALS PRESENTED AT MONTREAL HIV MEETING

 LAVAL, Quebec, May 13 /PRNewswire/ -- Interim data from the North American Phase I/II clinical trials of the anti-AIDS compound 3TC were presented today at the Third Annual Canadian Conference on HIV/AIDS Research in Montreal, BioChem Pharma Inc. (NASDAQ: BCHXF) announced today. Physicians who conducted the Phase I/II trials in North America presented clinical results from patients treated with 3TC over a period of about one year.
 The summary of the presentation shows 3TC to be well-tolerated, with no significant drug-related toxicity within the therapeutic dose range. As measured by surrogate markers, the drug exhibits anti-viral activity. These results corroborate the data disclosed at ICAAC in October 1992. The data presented at today's conference covers a period of about one year.
 Multi-center, double blind Phase II/III surrogate marker clinical trials are due to begin shortly in the United States, Canada and Europe.
 At the same conference, Dr. Mark Wainberg, of the Lady Davis Institute, McGill University, presented data on the "in vitro selection of HIV drug resistance against 3TC." Glaxo has an extensive program to evaluate resistance and neither the clinical relevance of resistance nor the correlation of in vitro to in vivo resistance is fully understood.
 More data on the Phase I/II clinical studies and on the issue of resistance will be presented at the forthcoming World AIDS Conference in Berlin in June.
 Glaxo is managing the development of 3TC as part of a collaborative agreement with BioChem Pharma that also covers commercialization of the drug. BioChem Pharma discovered, researched and patented 3TC.
 BioChem Pharma is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The company's shares are traded on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ stock market (BCHXF).
 -0- 5/13/93
 /CONTACT: Jean-Yves Duthel, vice president-public relations, of BioChem Pharma, 514-681-1744, or (cellular) 514-949-3714; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for BioChem Pharma/
 (BCHXF)


CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU:

TS-PS -- NY013 -- 7937 05/13/93 08:53 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1993
Words:353
Previous Article:TEXAS INSTRUMENTS ANNOUNCES PARTIAL REDEMPTION OF $2.26 DEPOSITARY SHARES
Next Article:NEW YORK STOCK EXCHANGE CLOSING, WEDNESDAY, MAY 12 /PRN/
Topics:


Related Articles
BIOCHEM PHARMA PRESIDENT TO COMMENT ON RESULTS OF PHASE I/II TESTS ON 3TC
PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM
3TC RESULTS TO BE SUBMITTED TO REGULATORY AUTHORITIES TO PROCEED TO DEFINITIVE PHASE OF TRIALS
3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS
3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS
BIOCHEM IS STILL GROWING
BIOCHEM IS STILL GROWING
LAMIVUDINE: EARLY PHASE II TRIAL RESULTS ENCOURAGING; LATE PHASE II TRIALS INITIATED
BIOCHEM PHARMA RECEIVES GO-AHEAD FROM U.S. FDA TO START PHASE I CLINICAL TRIAL WITH ITS NOVEL ANTI-HIV COMPOUND, BCH-10652
BIOCHEM PHARMA'S MANAGEMENT REVIEWS COMPANY'S FIVE-YEAR GROWTH PROSPECTS.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters